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• Pseudomonas aeruginosa (Pa) is a leading cause of lung infection
in patients with cystic fibrosis (CF), increasing morbidity and
mortality
• Inadequate and/or improper treatment of Pa infections can lead to
chronic colonization, making eradication more unlikely
• Despite numerous clinical trials, there is still no standardized
treatment among the medical community for Pa eradication in
patients with CF
• The Nebraska Regional Cystic Fibrosis Center at Children’s
Hospital and Medical Center (CHMC) in Omaha, Nebraska has
their own Pa eradication protocol

Figure 1. Pseudomonas aeruginosa Eradication
Protocol

Figure 2. Pseudomonas aeruginosa Colonization
Following Protocol vs Non-protocol Treatment.
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• As shown in figure 2, when the protocol was fully followed, 12/121
(9.9%) of patients become colonized with Pa compared to 27/51
(52.9%) of patients who did not follow the protocol (odds ratio
0.099, 95% CI 0.04-0.22, P-value= <0.0001)

• This study aims to increase Pa eradication for children with CF by
investigating the effectiveness and adherence to the current Pa
eradication protocol used at CHMC
• It is hypothesized that close adherence to the current Pa eradication
protocol will be associated with higher levels of eradication at each
step and patients will have lower levels of chronic colonization

Conclusion

Methods
• Retrospective medical chart review of 1–21 year-olds with CF at
CHMC
• Patients without enough documentation in their medical record to
extrapolate date were excluded
• Medical records were screened for Pa culture results and
subsequent treatments. Patient’s treatments not aligning with the
treatment protocol were considered getting “non-protocol
treatment”
• Primary endpoints measured included: degree of Pa protocol
adherence and eradication success and chronic colonization
following set protocol vs non-protocol treatments
• Current protocol (Figure 1) starts on Step 1 with inhaled
tobramycin x28 days and ciprofloxacin x14 days
• If sustained positivity, the patient is started on Step 2 with1014 days of intravenous antibiotics
• If still positive after this point, they progress to Step 3 with 6
months of alternating monthly inhaled tobramycin, colistin, or
aztreonam
• Patient is considered colonized if they are Pa positive following
Step 3
• After a negative sputum culture following a step, Pa is considered
eradicated, they continue quarterly monitoring, and they restart
the protocol following another positive Pa result

Treatment not following
protocol

Results
• 172 of the 184 patients on CHMC’s CF registry were included in the
study (8 excluded for age and 4 for inadequate medical records)
• Protocol was followed correctly for 70.3% of all patients

• Adherence to the current Pa eradication protocol was associated
with increased Pa eradication levels when used at step one.
However, there was no statistical significance when comparing
protocol steps two and three to non-protocol treatment
• Patients fully adhering to the protocol had fewer cases of Pa
colonization. However, 70.3% of patients fully followed the
protocol
• Limitations of this study: retrospective nature, inability to follow
treatment compliance, health status when screened for Pa,
confounding co-morbidities
• Further work is needed to compare CHMC’s Pa eradication
protocol to others to help create a globally standardized protocol.
Recurrent evaluation of CHMC’s current protocol will have to
proceed as advances in CF treatment continue (i.e. Trikafta)

Table 1. Pa Eradication Following Protocol Treatment vs Non-protocol
treatment.
Protocol
treatment
(%)
Step 1
eradication 151 (73.3%)
Step 2
eradication 22 (37.9%)
Step 3
eradication 10 (23.3%)

1Döring,

Non-protocol
treatment (%)

Odds ratio (95%
CI)

P-value

36 (59.0%)

0.52 (0.29-0.95)

0.03

11 (45.8%)

1.38 (0.53-3.62)

0.51

3 (75%)

9.9 (0.92-106.03)

0.06
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